Atomo Diagnostics Ltd (ASX: AT1) Share Price and News
Price
$0.017
Movement
0.00 (0.0)
as at 7 May - Closed (20 mins delayed)
52 Week Range
$0.016 - $0.044
1 Year Return
-43.33%
Atomo Diagnostics Ltd Chart and Price Data
2025
2025
2025
2025
$0.015
$0.02
$0.025
$0.015
$0.02
$0.025
$0.015
$0.02
$0.025
$0.015
$0.02
$0.025
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$10.87 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
639.20 million
Earnings per share
-0.010
Dividend per share
N/A
Year To Date Return
-10.53%
Earnings Yield
N/A
Franking
-
Share Price
$0.017
Day Change
0.00 (0.0)
52 Week Range
$0.016 - $0.044
Yesterday's Close
$0.017
Today's Open
$0.017
Days Range
$0.017 - $0.017
Volume
34,000
Avg. Volume (1 month)
835,906
Turnover
$578
as at 7 May - Closed
Atomo Diagnostics Ltd (ASX: AT1)
Latest News
Share Fallers
Why is the Atomo (ASX:AT1) share price trending downwards?
Share Market News
The Atomo Diagnostics (ASX:AT1) share price is popping 7% today
Share Market News
Why the Atomo Diagnostics (ASX:AT1) share price closed 7% down today
Share Market News
If only Ellume was an ASX share! Why it's making big news today
Share Market News
Atomo Diagnostics (ASX:AT1) posts 709% boost in quarterly cash receipts
Share Market News
Atomo (ASX:AT1) share price on watch following TGA approval
Share Market News
The Atomo (ASX:AT1) share price is up today. Here's why.
Share Market News
Why the Atomo (ASX:AT1) share price is flying 9% higher today
Growth Shares
Top ASX growth shares to buy in October 2020
Share Market News
Why the Atomo (ASX:AT1) share price is moving higher today
Share Market News
Atomo (ASX:AT1) share price rockets 10% on new agreement
Share Market News
3 ASX shares fighting COVID-19 and rewarding shareholders
AT1 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 5th May 2025 2025-05-05T17:00:32 | Final Director's Interest Notice x 3 | YesNo | 5:00pm | 6 | 92k |
| 5th May 2025 2025-05-05T16:58:17 | Initial Director's Interest Notice x 2 | YesNo | 4:58pm | 4 | 260k |
| 5th May 2025 2025-05-05T16:57:07 | Section 708A Cleansing Statement | YesNo | 4:57pm | 1 | 183k |
| 5th May 2025 2025-05-05T16:56:27 | Notification of cessation of securities - AT1 | YesNo | 4:56pm | 4 | 13k |
| 5th May 2025 2025-05-05T16:56:12 | Notification regarding unquoted securities - AT1 | YesNo | 4:56pm | 6 | 18k |
| 5th May 2025 2025-05-05T16:48:32 | Application for quotation of securities - AT1 | YesNo | 4:48pm | 6 | 16k |
| 5th May 2025 2025-05-05T11:55:41 | Update - Proposed issue of securities - AT1 | YesNo | 11:55am | 12 | 33k |
| 24th Apr 2025 2025-04-24T15:46:29 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 3:46pm | 11 | 1M |
| 24th Apr 2025 2025-04-24T10:12:08 | Proposed issue of securities - AT1 | YesNo | 10:12am | 12 | 33k |
| 24th Apr 2025 2025-04-24T10:12:03 | Atomo completes Capital Raise and undertakes Restructure | YesNo | 10:12am | 5 | 286k |
About Atomo Diagnostics Ltd
Atomo Diagnostics Limited is a medical device company. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions
AT1 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 May 2025 | $0.02 | $0.00 | 0.00% | 450,113 | $0.02 | $0.02 | $0.02 |
| 05 May 2025 | $0.02 | $0.00 | 0.00% | 1,266,941 | $0.02 | $0.02 | $0.02 |
| 02 May 2025 | $0.02 | $0.00 | 0.00% | 313,386 | $0.02 | $0.02 | $0.02 |
| 01 May 2025 | $0.02 | $0.00 | 0.00% | 2,554 | $0.02 | $0.02 | $0.02 |
| 30 Apr 2025 | $0.02 | $0.00 | 0.00% | 159,927 | $0.02 | $0.02 | $0.02 |
| 29 Apr 2025 | $0.02 | $0.00 | 0.00% | 1,130,244 | $0.02 | $0.02 | $0.02 |
| 28 Apr 2025 | $0.02 | $0.00 | 0.00% | 363,986 | $0.02 | $0.02 | $0.02 |
| 24 Apr 2025 | $0.02 | $0.00 | 0.00% | 883,724 | $0.02 | $0.02 | $0.02 |
| 16 Apr 2025 | $0.02 | $0.00 | 0.00% | 46,400 | $0.02 | $0.02 | $0.02 |
| 15 Apr 2025 | $0.02 | $0.00 | 0.00% | 1,935,640 | $0.02 | $0.02 | $0.02 |
| 14 Apr 2025 | $0.02 | $0.00 | 0.00% | 3,813,005 | $0.02 | $0.02 | $0.02 |
| 11 Apr 2025 | $0.02 | $0.00 | 0.00% | 4,739 | $0.02 | $0.02 | $0.02 |
| 10 Apr 2025 | $0.02 | $0.00 | 0.00% | 650,000 | $0.02 | $0.02 | $0.02 |
| 09 Apr 2025 | $0.02 | $0.00 | 0.00% | 949,217 | $0.02 | $0.02 | $0.02 |
| 08 Apr 2025 | $0.02 | $0.00 | 0.00% | 2,053,314 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 14 Apr 2025 | John Kelly | Expiry | 666,666 | $14,666 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr John Michael Kelly | FounderChief Executive OfficerManaging Director | Apr 2010 |
Mr Kelly has focused on developing and commercializing innovative healthcare products that enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the Mirage Swift and Activa mask systems.
|
| Dr Cheri Louise Walker | Non-Executive Director | Nov 2022 |
Dr Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Dr. Walker is currently the President, Chief Executive Officer, and Director of Rhinostics. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher. He is a member of the Risk Committee.
|
| Mr Anthony May | Non-Executive Director | May 2025 |
Mr May has held various Director roles across international corporations including Hoechst Germany, Microgenics Corporation USA, Fisher Scientific and Thermo Fisher Scientific. With experience across public and private pathology laboratories, as well as sales and management roles in the IVD supply sector, he has built a record in business leadership and strategic growth.
|
| Mr Patrick Cook | Non-Executive Director | May 2025 |
Mr Cook is a Non-Executive Director and Chair with over 20 years of board level experience and over 30 years experience in senior executive positions in medical devices & point-of-care diagnostics sectors within multinational and listed biotechnology companies Mr Cook currently serves as Non-Executive Director & previously Chair, at Workplace Drug Testing Australasia Ltd and as Committee Member & previously Member of the Executive at Animal Ethics Committee QUT. He previously served as Non-Executive Director & Chair at eWaste Connection Ltd, Board Member at Prostate Cancer Foundation of Australia (Qld).
|
| Mr Mathew Leslie Watkins | Company Secretary | Jun 2024 |
-
|
| Mathew Leslie Watkins | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| GZ Family Holdings Pty Ltd | 79,787,536 | 12.48% |
| Dalraida Holdings Pty Limited | 65,120,000 | 10.19% |
| Global Health Investment Fund | 64,811,280 | 10.14% |
| Mr Xiaoyi Lin | 11,880,000 | 1.86% |
| Grand Challenges Canada | 11,390,824 | 1.78% |
| Liverbird Pty Ltd | 10,931,653 | 1.71% |
| Australia West Holdings Pty | 10,500,000 | 1.64% |
| Australia North Holdings Pty | 9,580,000 | 1.50% |
| ID&E Pty Ltd | 9,032,248 | 1.41% |
| Mark Andrew Smith | 7,790,224 | 1.22% |
| Mr Ian Fredrick Johnson | 7,506,080 | 1.17% |
| John Michael Kelly | 7,370,248 | 1.15% |
| Leo James Lynch | 7,321,121 | 1.15% |
| Citicorp Nominees Pty Limited | 6,355,684 | 0.99% |
| Mr Ankur Choudhary | 5,887,126 | 0.92% |
| Ruth Karen Devney | 5,626,408 | 0.88% |
| Sokolov Pty Ltd | 4,031,888 | 0.63% |
| H & L Management Pty Ltd | 4,000,000 | 0.63% |
| Rue Des Rocs Pty Ltd | 3,800,000 | 0.59% |
| Miss Lisa Marie Mackenzie | 3,351,968 | 0.52% |